Sara O. Weiss, MD Director, Heart Failure Services Virginia Mason Medical Center September 8, 2012

Transcription

1 Sara O. Weiss, MD Director, Heart Failure Services Virginia Mason Medical Center September 8, 2012 Disclosure: Dr. Weiss has no significant financial interest in any of the products or manufacturers mentioned.

2 Outline Background Lifestyle Interventions Medical Therapy

3

4 Magnitude of the Problem HF is common: Increasing in prevalence 5.8 million Americans; 23 million worldwide Lifetime likelihood of developing HF: 20% over age 40 HF is expensive: $30 billion dollars (2010) HF is deadly: 20% mortality at 1 yr Heart Disease and Stroke Statistics Update: A Report From the American Heart Association; Circulation 2010

5 Prevalence and Incidence Prevalence of heart failure by sex and age (National Health and Nutrition Examination Survey: ). Incidence of heart failure (heart failure based on physician review of medical records and strict diagnostic criteria) by age and sex (Framingham Heart Study: ). Roger V L et al. Circulation 2011;123:e18-e209 Roger V L et al. Circulation 2011;123:e18-e209 Copyright American Heart Association Copyright American Heart Association

6 Prognosis Redfield et al. Circulation 1998; 98; 2282

7 Pathophysiology Hemodynamic Model Inadequate pump function Poor forward flow Unable to explain the progressive nature Negative Remodeling Neurohormonal Dysregulation Architectural distortion

8 Complex Neurohormonal Effects in Heart Failure Myocardial Insult Increased Load and Increased Wall Stress Reduced System Performance Activation of RAAS and SNS Altered Gene Expression Growth Remodeling Ischemia Energy Depletion Cytokine Expression Fetal Gene Program ANP, BNP LVH Abnormal Ca 2+ Handling Ventricular Dyssynchrony Necrosis Fibrosis Apoptosis Cell Death Organ Failure

9 Etiology Coronary Artery Dz Non-Ischemic Causes Hypertension EtOH Valvular disease Obesity Diabetes Tobacco Abuse Chemotherapy Viral Myocarditis Post-partum Hypertrophic CM Gheorghiade M, Bonow RO. Circulation 1998;97:

10 Diagnostic Pearls CLINICAL DIAGNOSIS Based on signs and symptoms Orthopnea, PND, weight gain Elevated JVD LE edema, ascites Supportive Testing ECHO CXR EKG Stress testing or angiogram

11 Diagnotic Pearls BNP Pearls One time measurement Should not be used to adjust diuretics Lower in obese pts Increased with age Increased in women Increased in CKD Troponin Frequently elevated in HF Low grade (ie. < 2.0) Flat Poor prognostic indicator

12

13 Lifestyle Modification Salt restriction 2000 mg/24 hr Fluid restriction 2000 cc/24 hr Daily Weight Log Call if weight increased 3 lbs in 1 day 5 lbs overall

14 Pharmacologic Therapy Diuretics Ace inhibitors/arb Beta blockers Aldosterone antagonists Hydralazine/Nitrates Digoxin

15 Diuretic Pearls Furosemide 6 hr half-life Variable oral bioavailability Torsemide & bumetinide Almost 100% oral bioavailability Ethacrynic Acid No sulfa moiety Furosemide IV Furosemide PO Torsemide PO/IV Bumetinide PO/IV 20 mg 40 mg 20 mg 1 mg

16 Thiazide Synergy Chlorothiazide IV Metolazone Hydrochlorothiazide Chlorthalidone

17 Ace Inhibitors/ARBs Afterload reduction Antagonize RAAS Reduce hospitalizations Improve survival SOLVD Investigators NEJM 1991; 325: 293

18 AceI Pearls AceI first line Cough more common in women Fear not! Hypotension Hyperkalemia Renal insufficiency

19 Mortality Beta Blockers MERIT-HF 1 COPERNICUS b -blocker 1.0 b -blocker 0.8 Placebo 0.8 Placebo 0.6 Risk 34% 0.6 Risk 35 % P= P< Metop Succ: n=1990 Placebo: n= Time (years) Carvedilol: n=1156 Placebo: n= MERIT-HF Study Group. Lancet 1999;353: Packer M, et al. N Engl J Med 2001;344:

20 Beta Blocker Pearls Euvolemic patients only Not all beta blockers are created equally Carvedilol Metoprolol Succinate (not metop tartate) Bisoprolol Fear not the bradycardia and hypotension! High dose is better than low dose

21 Mortality (%) Lancet 2003; 362:7-13 COMET Metoprolol tartate Carvedilol hazard ratio 0.83, 95% CI , p= Number at risk Time (years) Carvedilol Metop tart

22 Probability of Survival Aldosterone Antagonists Spironolactone Eplerenone RALES Placebo Spironolactone 27% mortality P< Months Pitt B et al. N Engl J Med. 1999;341:

23 Aldosterone Antagonist Pearls Weak diuretics Beware of hyperkalemia! Decrease/discontinue potassium supplementation Check levels frequently Contraindicated in renal insufficiency Women: Cr > 2.0 Men: Cr > 2.5

24 Hydralazine/Nitrates Potent vasodilator afterload reduction Increase NO formation VHeFT 1991 Hydralazine/ISDN v. enalapril Subgroup analysis of AA pts AHeft 2004

25 Hydralazine/Nitrate Pearls Must be used in combination TID dosing is difficult Rebound tachycardia Use with beta blockers

26 Event rate at 37 months (%) Cardiac Glycosides: Digoxin 40 P= 0.06 P= Digoxin Placebo Mortality HF hospitalization Digitalis Investigators. N Engl J Med 1997;336:

27 M ortality Ra Digoxin Pearls Narrow therapeutic window! DIG Trial Mortality Rates in Men by Trough Renal clearance Level Measured decreased 1 Month in elderly After Randomization in women Target level: Figure n = 1171 digoxin 2639 placebo Placebo Crude Rate Risk Adjusted Rate, digoxin Crude Rate, digoxin > = 2.0 Serum D igoxin Concentration

28

29 Percent of Patients Utilization of Evidence-based HF Therapies at University Hospitals b- ACE Inhibitors Blockers Spironolactone University Hospital Consortium HF Registry: 33 centers, 1239 patients, Year Outpatient regimen before HF hospitalization in patients with Stage C HF. Presented by Dr. Fonarow at the Heart Failure Society of America Satellite Symposium, September 23, Unpublished data courtesy of Dr. G. Fonarow, UCLA Medical Center.

30 Common Problems Inadequate access to care Non-adherence to HF teaching: Salt restriction Daily weights Recognition of symptoms Co-morbidities Polypharmacy Financial concerns Cognitive and functional limitations Inadequate social support Anxiety and depression

31 HF Program at VM Multi-disciplinary clinic 2 physicians 2 ARNPs 3 nurses Social worker Palliative care team Pharmacist EP and cath lab support Goals: Decrease re-admissions Improved patient education Improved quality of life Lower costs Provide a service: patients medical community

32

33 Stage v. NYHA Class ACC/AHA HF Stage 1 NYHA Functional Class 2 A At high risk for heart failure but without structural heart disease or symptoms of heart failure (ie: patients with HTN or CAD) B Structural heart disease but without symptoms of heart failure C Structural heart disease with prior or current symptoms of heart failure I Asymptomatic II Symptomatic with moderate exertion III Symptomatic with minimal exertion D Refractory heart failure requiring specialized interventions IV Symptomatic at rest 1 Hunt SA et al. J Am Coll Cardiol. 2001;38: New York Heart Association/Little Brown and Company, Adapted from: Farrell MH et al.jama.2002;287:

34 Device Therapy ICD LVEF < 35% Optimal medical management X 3 months CRT or BiV Optimal medical management QRS duration 120 msec NYHA class 2-4 symptoms